Bristol Myers Squibb

A Medicare pilot program called GUARD, aimed at lowering drug prices through 'most-favored nation' pricing, could lose significant savings if rare disease drugs are excluded, according to biotech lobbying efforts. Additionally, reports of potential mergers between AstraZeneca and Bristol Myers Squibb have been denied by anonymous sources.

A senior source denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks. A source close to the matter told Reuters there is 'no deal' and 'never was a deal to be done' between the two drugmakers.

AstraZeneca's potential merger with Bristol Myers Squibb could shift more of its revenue away from the UK and Europe, possibly leading to a New York relisting. US regulatory demands might require commitments to US research, manufacturing, and employment, further distancing the company from the UK. Recent trends show UK-based firms increasingly relisting in New York or being acquired by US rivals.

AstraZeneca and Bristol Myers Squibb are in talks that could result in a $400bn merger, creating the world’s fourth-largest drugmaker by market value.

AstraZeneca investors are expressing concerns about a potential $400 billion merger with Bristol Myers Squibb, citing risks related to an impending patent cliff and antitrust challenges.

AstraZeneca's stock fell amid merger talks with Bristol Myers Squibb, which could create a $400 billion drugmaker, while Amgen disclosed a cybersecurity incident involving stolen patient data. Investors questioned the strategic need for the proposed merger, and Bristol Myers Squibb's shares rose in premarket trading.

AstraZeneca stock declined following reports of merger discussions with Bristol Myers Squibb. The potential merger could create a company valued at nearly $400 billion, according to the Financial Times.

AstraZeneca is holding discussions with Bristol Myers Squibb regarding a potential £300 billion merger. The talks could result in a major business consolidation between the two companies.

AstraZeneca shares fell 7% following a Financial Times report indicating the company has discussed a potential merger with Bristol Myers Squibb over several months.

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. The deal would combine AstraZeneca's nearly £196bn market value with BMS's $133bn valuation.

AstraZeneca is in talks to acquire Bristol Myers Squibb in a potential $400bn merger, creating the world’s fourth-largest drugmaker. AstraZeneca, the UK’s second-biggest listed company, has a market value of nearly £196bn, while BMS, based in Princeton, is valued at $133bn.

AstraZeneca has explored an acquisition of Bristol Myers Squibb, though it is unclear if discussions are ongoing or will result in a transaction. AstraZeneca declined to comment, and Bristol Myers Squibb could not be reached for comment.

AstraZeneca and Bristol Myers Squibb are discussing a potential $400 billion merger. The article also references a migrant crossing in Ceuta and UEFA's response to a failed FIFA plan.

AstraZeneca is in talks with Bristol Myers Squibb to finalize a $400 billion megadeal, which would create one of the world's largest pharmaceutical groups with a combined value of nearly $400 billion.

AstraZeneca Plc explored an acquisition of Bristol Myers Squibb Co., which could create one of the world's largest drugmakers. Bristol Myers Squibb, with a $133 billion market capitalization, faces patent losses for key drugs like Eliquis and Opdivo, while AstraZeneca has a market value of about £196 billion. Bristol recently reported record quarterly sales of $13 billion driven by newer treatments.

AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world’s largest drugmakers.

U.K. pharmaceutical company AstraZeneca is in talks with U.S. rival Bristol Myers Squibb for a potential $400 billion merger, as reported by the Financial Times.

Bristol Myers Squibb is raising its full-year outlook after blood thinner sales exceeded expectations. Strong sales of Eliquis, Camzyos, and Reblozyl pushed second-quarter revenue to $12.97 billion, surpassing analyst estimates.

President Donald Trump announced a plan to impose 100% tariffs on generic drugs starting August 2028, increasing to 200% in 2029, aiming to reshape pharmaceutical production in the U.S. The administration has not yet issued a formal order, while brand-name drug tariffs remain unchanged. Exemptions and lower rates apply to companies building U.S. plants and certain trade partners.

Bristol Myers Squibb is implementing NVIDIA's Vera Rubin systems to accelerate drug discovery. The systems are described as the most powerful AI computing infrastructure in life sciences.

Bristol Myers Squibb is assembling the largest NVIDIA AI supercomputer in the life sciences industry, following a trend among pharma companies. The company expanded its computing power to develop foundation models for drug candidate interactions in areas like oncology and neurodegeneration.

A clinical trial showed improved outcomes for pancreatic cancer patients using a combination of Tango Therapeutics' PRMT5 inhibitor and Revolution Medicines' pan-RAS inhibitor. The article speculates on potential biotech mergers and acquisitions involving companies like Revolution Medicines, Tango Therapeutics, and Bristol Myers Squibb.

Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.

The Supreme Court rejected a challenge to the Medicare drug price negotiation program, declining to take up lawsuits from several pharmaceutical companies. The decision is a blow to the brand drug industry's legal campaign against the program. The court did not provide a reason for its decision.

Bristol Myers Squibb has partnered with a Chinese company to develop new drugs. This collaboration marks a potential next wave of cross-continent partnerships. The partnership aims to bring new treatments to market.

The pharmaceutical industry is calling for stability and predictability from the next FDA commissioner after a tumultuous period. The CEO of PhRMA, Steve Ubl, and Bristol Myers Squibb CEO Chris Boerner emphasized the need for a stable FDA to ensure certainty in drug development. The industry is also pushing back against President Trump's 'most favored nation' pricing policy.

Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.

Bristol Myers Squibb has partnered with Hengrui Pharma on over a dozen early-stage programs, including a $600 million upfront payment and a potential value of up to $15.2 billion. The deal grants Bristol rights to four Hengrui drug candidates outside of mainland China, Hong Kong, and Macau. Hengrui will commercialize four immunology drugs from Bristol in the region.